FeesSafety
Pluang+

Linus Torvalds uses AI to improve Linux kernel code but warns against careless AI patches.

Protocol Fundamentals
23 Oct 2026
Crypto Briefing
View Source
Bullish
Linus Torvalds uses AI to improve Linux kernel code but warns against careless AI patches.

Linus Torvalds, creator of the Linux kernel, has started using Anthropic's Claude Code AI tool to assist in writing and reviewing kernel code, notably improving performance in memory management patches. His experimental patches increased read throughput significantly but have not yet been merged into the mainline kernel. Torvalds emphasizes that AI is useful when used by experienced developers but warns against low-quality AI-generated patches submitted by those who do not understand the code. The Linux kernel community has also dropped the mandatory AI-assistance tag, focusing instead on code quality regardless of how it was produced.

Linus Torvalds' use of AI in Linux kernel code comes as 26 of 50 major cryptocurrencies on Pluang rose today. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 23, 2026 19:01 WIB: COTI rose 6.35% to Rp211 with 62% sell orders, DOT gained 4.70% to Rp21.211 with 89% buy orders, and ATOM increased 3.20% to Rp31.893 with 90% sell orders. Overall, 26 cryptocurrencies advanced while 23 declined.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
52 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
52 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
52 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App